| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 50.98 | 0.01 (+0.02%) | 41.58 - 53.45 | 2.1 million |
Market data as of 4:01PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 50.73 |
|---|---|
| Previous Close | 50.97 |
| Day's Range | 50.73 - 51.06 |
| Market Cap | 63.8B |
| Avg Volume (10 Day) | 2.1M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | |
| Dividend Yield | 1.90 (5.49%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Neutral |
|---|---|
| Avoids excess debt? | Neutral |
| Converting sales to profits? | Neutral |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Neutral |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Neutral |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Neutral |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Neutral |
| Has sufficient liquidity? | Neutral |
Getting Healthy with Acquisitions, New Products, and Favorable Court Rulings - Research Report on AstraZeneca, Herbalife, CardioNet, Cyberonics, and NuVasive
PR Newswire - Monday 06/17/2013 8:00 AM ET
AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®
Business Wire - Friday 06/14/2013 9:00 AM ET
AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based Therapies
Business Wire - Wednesday 06/12/2013 1:11 PM ET
Providing Quality Healthcare Through Long-term Investments, Divestitures, New Research, Clinical Trials Results - Research Report on AmerisourceBergen, Zoetis, AstraZeneca, Cardinal Health and Sanofi
PR Newswire - Wednesday 06/12/2013 8:00 AM ET
SumTotal Customers and Industry Leaders Kick off Talent Expansion™ Tour 2013
Business Wire - Tuesday 06/11/2013 11:02 AM ET
Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
PR Newswire - Thursday 06/06/2013 7:00 AM ET
Customers Vote SumTotal Finalist in Four Best of Elearning! 2013 Awards
Business Wire - Tuesday 06/04/2013 9:54 AM ET
U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca’s Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy
Business Wire - Tuesday 06/04/2013 9:03 AM ET
| AZN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|
Data is delayed by at least 15 min.